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performed to determine if gender was an independent predictor of guideline door-to-
balloon time of <90 min.
Results: Amongst 2032 pts with confirmed STEMI referred between May 2005 and
July 2010, 574 (28%) were women and 1458 (72%) were men. Women differed from
men in the following baseline characteristics: age, 68±14 vs. 60±12, p<0.0001,
hypertension, 58% vs. 45%, p<0.0001, smoking, 34% vs. 44%, p<0.0001, prior bypass
surgery, 2% vs. 4%, p=0.01, prior stroke, 9% vs. 6%, p=0.01, systolic blood pressure,
132±30 vs 136±29, p=0.001, BMI, 27±6 vs. 28±5, p=0.02, creatinine clearance, 65±28
vs. 76±29, p<0.0001, and Killip class 1 82% vs. 87%, p=0.008. Women were more
likely to call for an ambulance, 71% vs. 62%, p=0.0001. PCI was performed in 92%
of women and 94% of men, p=0.17. Women were less likely to be treated with stents,
88% vs. 92%, p=0.007. The median door-to-balloon time in women was 105 min
(IQR=79-137) vs. 99 min (IQR= 72-132) for men, p=0.005. The 30 day mortality was
7.5% in women vs. 4.8% in men, p=0.02. The results of the multivariable analysis to
determine predictors of door-to-balloon time <90 min are shown in the table.
Conclusion: In spite of standardized protocols implemented in a STEMI system,
women continue to have longer door-to-balloon times. Additional research is needed
to reduce delays to reperfusion in women.
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Background: The Responsiveness to CLOpidogrel and Stent-related Events in patients
with ACS(RECLOSE2-ACS) receiving PCI and for whom platelet reactivity after
clopidogrel loading was prospectively assessed. To test if high residual platelet
reactivity (HRPR) would be a prognostic marker of risk of thrombotic events and to
assess the relationship of diabetes mellitus (DM) with HRPR on clinical outcome.
Methods: Consecutive ACS patients undergoing PCI and platelet reactivity after 600
mg clopidogrel loading dose. Patients with HRPR (ADP 10 μmol ≥ 70%) received an
increased chronic dose of clopidogrel. DM was investigated according to insulin use.
The interaction between DM and HRPR on outcome was assessed by Cox analysis.
Primary end point: composite of cardiac death, MI, urgent PCI, and stroke at 2y FU.
ClinicalTrial.gov: NCT01231035.
Results: A total of 1789 patients were enrolled: 20% had DM: 11% were non-insulin
dependent (NIDD), 9% were insulin dependent (IDD) and 80% were non diabetic
(ND). HRPR incresead according to diabetic status: ND 12%, NIDD 18% and IDD
22% (p=.001). Most patients with HRPR remained with an ADP ≥ 70% after treatment
adjustment: ND 36%, NIDD 41% and IDD 43%. In patients with DM and HRPR, there
were no differences in the primary end point rate (15% vs 19%) after treatment
adjustment between patients with an ADP < 70% and with ADP ≥ 70%. HRPR and
IDD resulted independent predictors of the primary end point (HR 1.5 ; p=.032 and
HR 1.4; p=.029 respectively) and cardiac mortality (HR 1.7; p=.013 and HR 1.8;
p=.016). No interaction of HRPR with DM on outcome was found.
Conclusion: HRPR is two-fold higher in IDD as compared to ND. HRPR and IDD
are predictors of long-term clinical outcome in ACS patients receiving PCI. In DM
patients, treatment adjustment with first generation of thienopiridine, has not impact
on outcome. It is unknown if new antithrombotic agents (as prasugrel or ticagrelor)
will provide an improvement on clinical outcome.
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Background: Platelet reactivity after clopidogrel therapy varies among individuals.
This study was aimed to evaluate clinical impacts of clopidogrel response variability
and the covariant factors in Asian populations undergoing elective percutaneous
coronary intervention (PCI).
Methods: Patients receiving clopidogrel after elective PCI were prospectively followed
up. Platelet reactivity after clopidogrel therapy was measured with the VerifyNow
P2Y12 assay. The primary endpoints were stent thrombosis and the composite of
cardiac death and non-fatal myocardial infarction (MI) at 2 year.
Results: Among 160 patients (average year of age 62.1±12.9 with 83.5% male in
gender), the average of P2Y12 reaction unit (PRU) was 239.0±85.8 and the average
of inhibition was 0.29±0.22%. Distribution of P2Y12 reaction units (PRU) in this study
cohort was higher than Caucasian reports. Hyporesponders were defined as those with
PRU >275, which was derived from an ROC curve analysis. The background
characteristics were similar in both groups except for diabetes mellitus (DM) (higher
PRU vs. low PRU: 57% vs. 35%; p<0.05). The average PRU of patients with DM was
significantly higher than those without DM (273.7±70.7 vs. 213.2±87.8; p=0.005).
Patients with high PRU levels also had significantly higher rates of both the composite
events (2.4% vs. 0.8%, p=0.04), and stent thrombosis rate (1.8% vs. 0.2%; p=0.03)
compared to normal responders. Multivariable-adjusted analysis showed that PRU
>275 remains an independent predictor of the clinical composite endpoints.
Conclusion: Clopidogrel hypo-responsiveness was significantly associated with
cardiovascular outcome in patients undergoing elective PCI at 2 year. DM contributes
greatly to Asian populations’ platelet reactivity. We should consider ethnic differences
when choosing the cutoff value of PRU.
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Background: The insulin-sensitizing agents (rosiglitazone, pioglitazone) reduced
neointimal proliferation in patients with diabetes mellitus (DM) who underwent
percutaneous coronary intervention (PCI) with bare metal stents via the PPAR-r
receptor. We evaluated the clinical outcomes, angiographic results and intravascular
ultrasound (IVUS) results of patients taking pioglitazone after PCI.
Methods: This study was a single center, prospective randomized study. The study
population currently included 121 diabetic patients with coronary artery disease,
assigned to 51 patients taking 15mg of low dose pioglitazone daily in addition to their
diabetic medications and 70 patients without pioglitazone. We have analyzed the
clinical outcomes, angiographic results, IVUS results and the effects on the lipid profile
after 12 months of treatment.
Results: Ninety-seven patients completed follow-up angiography. Among them,
follow-up IVUS was done in fifteen patients. There were no significant differences
between the pioglitazone group and the control group of the baseline clinical
demographics and angiographic findings. The average lesion length and reference
diameter (RD) were 27.2±10.8 mm vs. 27.9±13.2 mm and 2.61±0.46 mm vs. 2.67±0.43
mm in the pioglitazone group and the control group, respectively. After 12 months of
medication, total triglyceride and LDL levels were decreased in the pioglitazone group
compared to control group statistically insignificant. There was no difference of major
cardiac adverse events (MACE), TLR, TVR and The rate of in-stent restenosis(ISR)
between two groups. There were statistically no difference of neointimal volume,
percent neotintmal volume, percent atheroma volume and normalized total atheroma
volume between two groups on IVUS study.
Conclusion: The results of this study showed that low dose pioglitazone, in diabetic
patients who underwent PCI, was not associated with reduced MACE, TLR, non-TVR
and restenosis. And, low dose pioglitazone didn’t affect atheroma plaques and
neointimal proliferation in the stents by IVUS.
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Background: In a roughly 25% of patients (p) Drug Eluting Stents (DES) are not
recommended due to specific clinical reasons that make prolonged use of clopidogrel
not appropriated. A remarkable percentage of these p have diabetes mellitus (DM), a
well known risk factor for stent restenosis. Our aim was to evaluate, in a prospective
randomized trial, whether in DM-p the titanium stent (T), a bioactive bare metal stent
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